By Abigail Townsend
Date: Thursday 26 Feb 2026
(Sharecast News) - Shares in Hikma Pharmaceuticals tumbled on Thursday, after the generics drugmaker withdrew its medium-term guidance and adopted a cautious outlook for the current year.
The group posted a 5% uplift in core revenues to $3.35bn in the year to December end, and a 3% improvement in core operating...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news